UTMD RSI Chart
Last 7 days
-1.0%
Last 30 days
-5.3%
Last 90 days
-19.6%
Trailing 12 Months
-22.6%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 52.5M | 51.9M | 51.5M | 50.2M |
2022 | 50.4M | 51.2M | 51.6M | 52.3M |
2021 | 42.2M | 46.1M | 48.1M | 49.1M |
2020 | 47.1M | 44.0M | 42.0M | 42.2M |
2019 | 41.8M | 42.7M | 44.8M | 46.9M |
2018 | 42.0M | 42.2M | 42.4M | 42.0M |
2017 | 39.3M | 39.6M | 40.1M | 41.4M |
2016 | 40.2M | 40.3M | 40.0M | 39.3M |
2015 | 41.7M | 41.6M | 40.8M | 40.2M |
2014 | 39.9M | 40.4M | 41.1M | 41.3M |
2013 | 40.7M | 40.7M | 40.2M | 40.5M |
2012 | 42.3M | 41.9M | 41.6M | 41.6M |
2011 | 25.5M | 29.6M | 34.2M | 37.9M |
2010 | 0 | 25.7M | 25.4M | 25.1M |
2009 | 0 | 0 | 0 | 25.9M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jun 15, 2023 | koopman brian | gifted | -5,658 | 94.31 | -60.00 | principal financial officer |
May 18, 2023 | richins paul o | sold | -65,429 | 93.47 | -700 | - |
Mar 17, 2023 | richins paul o | gifted | -13,875 | 92.5 | -150 | - |
Feb 08, 2023 | payne barbara a | gifted | -44,998 | 89.9974 | -500 | - |
Dec 06, 2022 | koopman brian | acquired | 37,320 | 74.64 | 500 | principal financial officer |
Dec 06, 2022 | koopman brian | sold (taxes) | -37,288 | 101 | -366 | principal financial officer |
Nov 18, 2022 | richins paul o | sold | -40,773 | 90.81 | -449 | - |
Nov 17, 2022 | richins paul o | sold | -14,490 | 90.00 | -161 | - |
Nov 11, 2022 | richins paul o | sold | -3,700 | 92.5 | -40.00 | - |
Oct 31, 2022 | koopman brian | gifted | -5,781 | 88.94 | -65.00 | principal financial officer |
Which funds bought or sold UTMD recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | unchanged | - | -577 | 27,287 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 1.53 | -81,949 | 14,379,600 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 68.53 | 2,290,990 | 5,813,200 | -% |
Feb 28, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | reduced | -0.35 | -3,553 | 143,679 | -% |
Feb 16, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | reduced | -8.26 | -210,000 | 1,853,000 | -% |
Feb 15, 2024 | MERCER GLOBAL ADVISORS INC /ADV | reduced | -0.23 | -8,000 | 370,000 | -% |
Feb 15, 2024 | Legal & General Group Plc | added | 30.02 | 11,117 | 51,795 | -% |
Feb 15, 2024 | BARCLAYS PLC | added | 626 | 344,000 | 401,000 | -% |
Feb 14, 2024 | LAZARD ASSET MANAGEMENT LLC | added | 493 | 117,000 | 141,000 | -% |
Feb 14, 2024 | TWO SIGMA INVESTMENTS, LP | reduced | -29.89 | -288,562 | 632,240 | -% |
Unveiling Utah Medical Products Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Utah Medical Products Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | -1.4% | 12.00 | 13.00 | 13.00 | 13.00 | 14.00 | 13.00 | 13.00 | 12.00 | 13.00 | 13.00 | 13.00 | 11.00 | 12.00 | 10.00 | 9.00 | 11.00 | 12.00 | 12.00 | 12.00 | 11.00 | 10.00 |
Gross Profit | -3.5% | 7.00 | 7.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 8.00 | 7.00 | 7.00 | 6.00 | 5.00 | 7.00 | 8.00 | 7.00 | 8.00 | 7.00 | 6.00 |
Operating Expenses | -100.0% | - | 3.00 | 3.00 | 3.00 | - | 3.00 | 3.00 | 3.00 | - | 3.00 | 3.00 | 3.00 | - | 3.00 | 3.00 | 3.00 | - | 3.00 | 3.00 | 3.00 | - |
S&GA Expenses | -100.0% | - | 3.00 | 3.00 | 3.00 | -7.27 | 3.00 | 3.00 | 3.00 | -7.25 | 3.00 | 3.00 | 3.00 | -6.93 | 3.00 | 3.00 | 3.00 | -6.60 | 3.00 | 3.00 | 3.00 | -3.72 |
R&D Expenses | 5.4% | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EBITDA Margin | -0.3% | 0.41* | 0.41* | 0.42* | 0.42* | 0.41* | 0.41* | 0.40* | 0.40* | 0.40* | 0.39* | 0.38* | 0.34* | 0.35* | 0.36* | - | - | - | - | - | - | - |
Income Taxes | -13.6% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Earnings Before Taxes | 4.9% | 5.00 | 5.00 | 5.00 | 5.00 | 6.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 4.00 | 4.00 | 4.00 | 2.00 | 4.00 | 5.00 | 4.00 | 5.00 | 4.00 | 4.00 |
EBT Margin | -0.4% | 0.40* | 0.40* | 0.41* | 0.40* | 0.40* | 0.39* | 0.39* | 0.39* | 0.39* | 0.38* | 0.36* | 0.33* | 0.33* | 0.34* | - | - | - | - | - | - | - |
Net Income | -100.0% | - | 4.00 | 4.00 | 4.00 | 5.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 1.00 | 3.00 | 4.00 | 4.00 | 4.00 | 3.00 | 3.00 |
Net Income Margin | 2.5% | 0.34* | 0.33* | 0.33* | 0.33* | 0.32* | 0.31* | 0.31* | 0.30* | 0.30* | 0.29* | 0.28* | 0.25* | 0.26* | 0.28* | - | - | - | - | - | - | - |
Free Cashflow | 6.2% | 5.00 | 5.00 | 5.00 | 7.00 | 6.00 | 5.00 | 5.00 | 5.00 | 5.00 | 6.00 | 4.00 | 6.00 | 6.00 | 5.00 | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | 3.2% | 135 | 131 | 130 | 128 | 124 | 118 | 116 | 120 | 116 | 120 | 117 | 114 | 112 | 107 | 104 | 103 | 110 | 104 | 103 | 105 | 100 |
Current Assets | 4.3% | 106 | 102 | 99.00 | 95.00 | 90.00 | 84.00 | 79.00 | 79.00 | 73.00 | 76.00 | 71.00 | 67.00 | 62.00 | 57.00 | 53.00 | 51.00 | 55.00 | 50.00 | 46.00 | 46.00 | 61.00 |
Cash Equivalents | 5.3% | 93.00 | 88.00 | 85.00 | 81.00 | 75.00 | 70.00 | 66.00 | 66.00 | 61.00 | 64.00 | 60.00 | 56.00 | 52.00 | 46.00 | 42.00 | 40.00 | 43.00 | 37.00 | 33.00 | 33.00 | 51.00 |
Inventory | -1.3% | 10.00 | 10.00 | 10.00 | 10.00 | 9.00 | 8.00 | 7.00 | 7.00 | 7.00 | 6.00 | 6.00 | 6.00 | 6.00 | 6.00 | 7.00 | 7.00 | 7.00 | 6.00 | 8.00 | 8.00 | 7.00 |
Net PPE | 2.0% | 11.00 | 10.00 | 11.00 | 10.00 | 10.00 | 10.00 | 10.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 11.00 | 10.00 | 10.00 | 11.00 | 10.00 | 10.00 | 10.00 | 10.00 |
Goodwill | 2.0% | 14.00 | 13.00 | 14.00 | 14.00 | 13.00 | 13.00 | 13.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 14.00 | 13.00 | 14.00 | 14.00 | 14.00 |
Liabilities | -5.3% | 7.00 | 8.00 | 9.00 | 10.00 | 10.00 | 10.00 | 9.00 | 11.00 | 8.00 | 10.00 | 9.00 | 10.00 | 9.00 | 9.00 | 8.00 | 9.00 | 9.00 | 9.00 | 9.00 | 13.00 | 11.00 |
Current Liabilities | 12.8% | 5.00 | 4.00 | 5.00 | 6.00 | 6.00 | 6.00 | 4.00 | 6.00 | 4.00 | 5.00 | 4.00 | 5.00 | 4.00 | 4.00 | 3.00 | 4.00 | 3.00 | 4.00 | 4.00 | 7.00 | 5.00 |
Shareholder's Equity | 3.7% | 128 | 124 | 122 | 118 | 114 | 108 | 107 | 109 | 107 | 110 | 107 | 105 | 103 | 98.00 | 95.00 | 94.00 | 101 | 95.00 | 94.00 | 92.00 | 89.00 |
Retained Earnings | 2.4% | 138 | 135 | 132 | 129 | 126 | 123 | 119 | 118 | 115 | 118 | 115 | 113 | 111 | 109 | 107 | 107 | 111 | 107 | 105 | 102 | 100 |
Additional Paid-In Capital | 14.0% | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | - | 0.00 | - | - | 0.00 | 0.00 |
Shares Outstanding | 0.0% | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | - | - | - | - | - | - | - | - |
Float | - | - | - | - | - | - | - | 336 | - | - | - | 286 | - | - | - | 298 | - | - | - | 327 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 4.1% | 5,332 | 5,121 | 4,913 | 6,915 | 5,680 | 5,589 | 4,832 | 5,046 | 4,987 | 5,991 | 4,692 | 5,533 | 5,778 | 5,008 | 3,677 | 5,674 | 5,641 | 6,372 | 1,683 | 3,360 | 4,483 |
Share Based Compensation | 35.8% | 72.00 | 53.00 | 50.00 | 50.00 | 62.00 | 38.00 | 40.00 | 43.00 | 43.00 | 41.00 | 41.00 | 41.00 | 39.00 | 49.00 | 49.00 | 23.00 | 28.00 | 29.00 | 28.00 | 28.00 | 11.00 |
Cashflow From Investing | 51.6% | -90.00 | -186 | -320 | -43.00 | -38.00 | -321 | -222 | -237 | -253 | -77.00 | -212 | -10.00 | -54.00 | -95.00 | -257 | -454 | -288 | -122 | -118 | -21,012 | -147 |
Cashflow From Financing | -3.5% | -1,071 | -1,035 | -1,010 | -1,049 | -920 | -1,032 | -3,551 | 19.00 | -8,070 | -850 | -1,036 | -949 | -942 | -1,368 | -1,004 | -7,420 | -969 | -976 | -1,352 | -930 | -2,195 |
Dividend Payments | 0% | 1,071 | 1,071 | 1,070 | 1,070 | 1,051 | 1,052 | 1,060 | - | 8,349 | 1,039 | 1,039 | 1,038 | 1,019 | 1,020 | 1,035 | 1,042 | 1,029 | 1,028 | 1,028 | 1,027 | 1,008 |
Buy Backs | - | - | - | - | - | - | - | -2,495 | - | - | - | - | - | 6,976 | -551 | - | -6,426 | 398 | - | -398 | - | 1,205 |
UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENTS OF INCOME | |||
Sales, net (notes 1, 3, 9 and 11) | $ 50,224 | $ 52,281 | $ 49,054 |
Cost of goods sold | 20,186 | 20,085 | 18,137 |
Gross profit | 30,038 | 32,196 | 30,917 |
Sales and marketing | 1,685 | 1,507 | 1,414 |
Research and development | 560 | 493 | 526 |
General and administrative | 11,016 | 10,406 | 10,097 |
Operating income | 16,777 | 19,790 | 18,880 |
Dividend and interest income | 3,036 | 661 | 166 |
Royalty income (note 12) | 20 | 20 | 15 |
Other, net | 256 | 188 | 0 |
Income before provision for income taxes | 20,089 | 20,659 | 19,061 |
Provision for income taxes (note 7) | 3,454 | 4,186 | 4,273 |
Net income | $ 16,635 | $ 16,473 | $ 14,788 |
Earnings per common share (basic) (note 1) | $ 4.58 | $ 4.53 | $ 4.05 |
Earnings per common share (diluted) (note 1) | $ 4.57 | $ 4.52 | $ 4.04 |
Other comprehensive income (loss) | |||
Foreign currency translation net of taxes of $0 in all periods | $ 1,381 | $ (2,986) | $ (773) |
Total comprehensive income | $ 18,016 | $ 13,487 | $ 14,015 |
UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets | ||
Cash | $ 92,868 | $ 75,052 |
Accounts and other receivables, net (note 2) | 3,391 | 5,538 |
Inventories (note 2) | 9,582 | 8,814 |
Prepaid expenses and other current assets | 428 | 515 |
Total current assets | 106,269 | 89,919 |
Property and equipment, net (notes 4 and 10) | 10,551 | 10,224 |
Goodwill | 13,692 | 13,354 |
Other intangible assets (note 2) | $ 54,296 | $ 52,755 |
Operating Lease, Right-of-Use Asset, Statement of Financial Position | Other intangible assets (note 2) | Other intangible assets (note 2) |
Other intangible assets - accumulated amortization | $ (49,350) | $ (42,378) |
Other intangible assets, net (note 2) | 4,946 | 10,377 |
Total assets | 135,458 | 123,874 |
Current liabilities | ||
Accounts payable | 769 | 1,218 |
Accrued expenses (note 2) | $ 3,941 | 4,742 |
Operating Lease, Liability, Current, Statement of Financial Position | Accrued expenses (note 2) | |
Total current liabilities | $ 4,710 | 5,960 |
Long term lease liability | 295 | 341 |
Long term income tax payable (REPAT tax) (note 7) | 698 | 1,256 |
Deferred tax liability - intangible assets | 1,120 | 1,514 |
Deferred income taxes (note 7) | 322 | 549 |
Total liabilities | 7,145 | 9,620 |
Commitments and contingencies (notes 6 and 12) | 0 | 0 |
Stockholders' equity | ||
Common stock, $.01 par value; 50,000 shares authorized, issued 3,630 shares in 2023 and 3,628 shares in 2022 | 36 | 36 |
Accumulated other comprehensive loss | (10,658) | (12,039) |
Additional paid-in capital | 594 | 251 |
Retained earnings | 138,341 | 126,006 |
Total stockholders' equity | 128,313 | 114,254 |
Total liabilities and stockholders' equity | $ 135,458 | $ 123,874 |